Table 2.
Kaplan‐Meier Estimates for Risk of MACEs by Baseline HbA1c in Patients With DM in the ACCELERATE Trial
| End Point | HbA1c, % | P Value | |||||
|---|---|---|---|---|---|---|---|
| <6.0 (N=1418) | 6.0–<6.5 (N=1620) | 6.5–<7.0 N=1554) | 7.0–<7.5 (N=1111) | 7.5–<8.0 (N=792) | ≥8.0 (N=1650) | ||
| MACE | 168 (12.6) | 212 (14.5) | 201 (14.0) | 163 (16.1) | 117 (16.3) | 278 (18.2) | <0.001 |
| Cardiovascular death/MI/stroke | 101 (7.8) | 130 (8.9) | 111 (7.8) | 83 (7.9) | 58 (8.0) | 172 (11.3) | 0.003 |
| Cardiovascular death | 45 (3.4) | 41 (3.0) | 42 (2.9) | 36 (3.6) | 18 (2.6) | 63 (4.3) | 0.21 |
| All‐cause mortality | 63 (4.8) | 69 (5.0) | 71 (4.9) | 50 (5.0) | 35 (5.1) | 88 (5.9) | 0.21 |
| Nonfatal MI | 41 (3.1) | 84 (5.6) | 58 (4.1) | 46 (4.3) | 35 (5.0) | 106 (7.0) | <0.001 |
| Stroke | 27 (2.3) | 22 (1.5) | 27 (2.0) | 14 (1.4) | 13 (1.8) | 35 (2.4) | 0.45 |
| Revascularization | 96 (7.3) | 142 (9.6) | 125 (8.9) | 99 (10.3) | 75 (10.4) | 168 (11.1) | 0.001 |
| Hospitalization for unstable angina | 31 (2.3) | 25 (1.8) | 40 (2.8) | 46 (5.0) | 23 (3.1) | 52 (3.4) | 0.003 |
Data are given as number of patients (Kaplan‐Meier estimate). MACEs include cardiovascular death, nonfatal MI, cerebrovascular accident, hospitalization for unstable angina, and revascularization. ACCELERATE indicates Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes; DM, diabetes mellitus; HbA1c, hemoglobin A1c; MACE, major adverse cardiovascular event; MI, myocardial infarction.